Sugi Predict

Sugi Predict / Compounds / SCHEMBL194023

SCHEMBL194023

SCHEMBL194023

CC(C(=O)c1ccccc1)C(C#N)C#N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 7/20 0.46
▸ ALDH1A1 P00352 6/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ NPSR1 Q6W5P4 3/20 0.46
▸ CYP3A4 P08684 2/20 0.45
▸ TSHR P16473 2/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ PGR P06401 1/20 0.44
▸ ADRA2A P08913 1/20 0.44
▸ ADRA2B P18089 1/20 0.44
▸ HTR2A P28223 1/20 0.44
▸ HRH1 P35367 1/20 0.44
▸ KCNH2 Q12809 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ CES2 O00748 2/20 0.42
▸ CES1 P23141 2/20 0.42
▸ SLC6A2 P23975 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41
▸ MAPT P10636 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5746092 0.84 LMNA (0.43) LMNAALDH1A1SMN1; SMN2NPSR1CYP3A4
SCHEMBL13039632 0.81 LMNA (0.56) LMNAALDH1A1SMN1; SMN2NPSR1CYP3A4
SCHEMBL741168 0.80 PGR (0.47) LMNAALDH1A1SMN1; SMN2NPSR1CYP3A4
SCHEMBL12251084 0.79 LMNA (0.55) LMNAALDH1A1SMN1; SMN2NPSR1CYP3A4
SCHEMBL15834920 0.79 LMNA (0.55) LMNAALDH1A1SMN1; SMN2NPSR1CYP3A4
SCHEMBL11434598 0.77 PGR (0.44) LMNAALDH1A1SMN1; SMN2NPSR1CYP3A4
Biphenyl SCHEMBL27609018 0.76 LMNA (0.46) LMNAALDH1A1SMN1; SMN2PGRADRA2A
SCHEMBL23091851 0.75 TDP1 (0.50) LMNAALDH1A1SMN1; SMN2NPSR1CYP3A4
SCHEMBL408412 0.75 TDP1 (0.50) LMNAALDH1A1SMN1; SMN2NPSR1CYP3A4
SCHEMBL22163778 0.75 LMNA (0.54) LMNAALDH1A1SMN1; SMN2NPSR1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12351553-B2 Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-07-08 — — US disclosed
US-20230088365-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-03-23 — — US disclosed
US-11498898-B2 Process for producing pyrrole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-11-15 — — US disclosed
CN-114835619-A Process for preparing azole compounds 武田药品工业株式会社 2022-08-02 — — CN disclosed
EP-3929187-A2 PROCESS FOR PRODUCING PYRROLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2021-12-29 — — EP disclosed
US-20210070705-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-11 — — US disclosed
US-10844011-B2 Process for producing pyrrole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-11-24 — — US disclosed
US-20200115336-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2020-04-16 — — US disclosed
EP-3613734-A2 PROCESS FOR PRODUCING PYRROLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2020-02-26 — — EP disclosed
EP-3241826-A2 PROCESS FOR PRODUCING PYRROLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-11-08 — — EP disclosed
EP-2765130-B1 Intermediates for use in a process of producing pyrrole compounds TAKEDA PHARMACEUTICALS CO (JP) 2017-07-26 — — EP disclosed
EP-2402313-B1 PROCESS FOR PRODUCING PYRROLE COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-08-24 — — EP disclosed
US-9266831-B2 Process for producing pyrrole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-23 — — US disclosed
US-20140303378-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND TAKEDA PHARMACEUTICAL (JP) 2014-10-09 — — US disclosed
US-8822694-B2 Process for producing pyrrole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-09-02 — — US disclosed
EP-2765130-A2 Process for producing pyrrole compound Takeda Pharmaceutical Company Limited (JP) 2014-08-13 — — EP disclosed
EP-2402313-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2012-01-04 — — EP disclosed
US-20110306769-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070705-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND DHPS, STS, HPD LMNA 4586/4885ALDH1A1 1184/4885SMN1; SMN2 3160/4885
US-20200115336-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND DHPS, STS, HPD LMNA 4586/4885ALDH1A1 1184/4885SMN1; SMN2 3160/4885
US-12351553-B2 Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation CYP51A1, PAH, HPD LMNA 3456/4885ALDH1A1 1045/4885SMN1; SMN2 4810/4885
US-20230088365-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND DHPS, STS, HPD LMNA 4586/4885ALDH1A1 1184/4885SMN1; SMN2 3160/4885
US-11498898-B2 Process for producing pyrrole compound DHPS, STS, HPD LMNA 4586/4885ALDH1A1 1184/4885SMN1; SMN2 3160/4885
US-20140303378-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND DHPS, STS, HPD LMNA 4586/4885ALDH1A1 1184/4885SMN1; SMN2 3160/4885
US-10844011-B2 Process for producing pyrrole compound DHPS, STS, HPD LMNA 4586/4885ALDH1A1 1184/4885SMN1; SMN2 3160/4885
US-20110306769-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND DHPS, STS, HPD LMNA 4586/4885ALDH1A1 1184/4885SMN1; SMN2 3160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.